The global nicotine gum market was estimated at USD 1.30 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 5.6% from 2023 to 2030. The demand for nicotine replacement therapy (NRT) products, including nicotine gum, has been increasing globally in recent years as more people are opting for methods to quit smoking and reduce their exposure to the harmful chemicals found in tobacco smoke. Some of the latest trends in the global NRT market include the development of more convenient and effective NRT products, such as long-lasting gums, and the growing popularity of flavored options. In addition, there has been an increase in the number of people using NRT products to quit smoking, as well as a rise in the number of healthcare professionals recommending NRT products to their patients.
The COVID-19 pandemic had a significant impact on the nicotine gum market. The lockdowns and restrictions imposed during the pandemic caused a significant increase in stress and anxiety levels among people, leading to a rise in smoking and nicotine use. As a result, the demand for nicotine gum and other nicotine replacement therapy (NRT) products increased as people opted for ways to quit smoking or manage their nicotine cravings.
The pandemic caused disruptions to supply chains, resulting in temporary shortages of some NRT products, including nicotine gum. This led to price hikes and difficulties in obtaining certain products, which created challenges for smokers who were trying to quit.
Moreover, the growing recognition of nicotine replacement therapy, including nicotine gum, as a safe and effective way to quit smoking has led to increased demand for these products. In addition, manufacturers are also investing in marketing & promoting nicotine and in R&D to create new and improved nicotine gum products. This includes the development of products with new flavors, enhanced efficacy, and more convenient delivery systems, which contribute to market expansion. Healthcare providers are also increasingly recommending and prescribing nicotine replacement therapy, including nicotine gum, to quit smoking.
Governments around the world have also recognized the role that NRT can play in helping people quit smoking and have taken steps to support its use. Many countries have included NRT products, such as nicotine gum, as part of their smoking cessation programs and have provided funding for research. For instance, Japan offers smoking cessation drugs & therapy which is available to all and is reimbursable under the National Health Insurance. In addition, some governments have implemented regulations to make NRT products more widely available and accessible to those who need them. The FDA is a regulatory authority in the U.S. that governs approval for the marketing of new drugs for human use under the United States Federal Food, Drug, and Cosmetic Act 1938.
The 2mg segment dominated the market and accounted for the largest revenue share of 55.9% in 2022. People consume 2mg of nicotine gums as a form of nicotine replacement therapy (NRT) to help them quit smoking or to reduce their cigarette consumption. There is a growing awareness of the health risks associated with smoking, which has led to an increase in the number of people looking for ways to quit or reduce their smoking.
The 4mg segment is projected to grow at a CAGR of 6.0% during the forecast period. People who consume 4mg of nicotine gum are typically heavy smokers, meaning they smoke 25 or more cigarettes per day. The higher dose of nicotine in the 4mg gum is intended to help smokers manage their nicotine cravings and withdrawal symptoms more effectively, as heavy smokers typically require a higher dose of nicotine to achieve relief.
The pharmacies segment dominated the market and accounted for the largest revenue share of 38.4% in 2022. People buy nicotine gum from pharmacies for the medical advice and support available, the convenience of purchasing it along with other health-related products, the availability of the product, the quality of the product, and the confidentiality it offers. Moreover, pharmacies are staffed by trained professionals who can provide advice and information about nicotine gum and other nicotine replacement products.
The online distribution channel segment is estimated to grow at a CAGR of about 6.9% during the forecast period. This segment has witnessed immense popularity over the past few years. The shift in consumer preference toward online channels is due to the convenience that the channel provides, such as high discounts, availability of a diverse range of products on a single platform, easy payment methods, on-door delivery, and others. Additionally, online retailers often carry a large variety of nicotine gums with different flavors, strengths, and brands, compared to traditional brick-and-mortar stores. It allows consumers to choose the product that best fits their needs.
North America dominated the nicotine gum market and accounted for the largest revenue share of 29.9% in 2022. The percentage of health-conscious consumers in North America has increased as a result of campaigns and government initiatives that have stimulated market growth in the region. In addition, the region is home to notable brands like Johnson & Johnson, Cipla Health Limited, Philip Morris, and others that prioritize product innovation in order to meet the market's growing demand and gain a competitive edge.
Asia Pacific is expected to witness a CAGR of 6.5% from 2023 to 2030. This factor is attributable to the increasing demand for innovative products, the intensifying competition among the major tobacco companies, and the expansion of market opportunities, particularly in Japan. In addition, stringent anti-smoking regulations in India and China are anticipated to increase the demand for nicotine replacement products such as gums.
The industry is characterized by the presence of some large multinational and regional companies. Leading manufacturers hold a significant market share across the globe. Companies have been implementing various expansion strategies such as mergers & acquisitions, and capacity expansions, to stay competitive.
In July 2021, Philip Morris acquired nicotine gum manufacturer Fertin Pharma from a private equity firm for USD 813.1 million in an effort to expand its smoke-free portfolio. Fertin Pharma's products include tablets, chewing gums, and powders with pharmaceutical and nutraceutical applications that help people quit smoking.
In May 2019, Nicorette introduced a nicotine gum product coated with ice mint lozenge for a smoother mouthfeel. Some of the prominent players in the global nicotine gum market include:
Johnson & Johnson
Novartis AG
ITC Limited
Cipla Health Limited
Perrigo Company Plc.
Teva Canada
Philip Morris
British American Tobacco PLC
Report Attribute |
Details |
Market size value in 2023 |
USD 1365.7 million |
Revenue forecast in 2030 |
USD 2.0 billion |
Growth Rate |
CAGR of 5.6% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2017 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million, CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Type, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; China; Japan; India; South Korea; Brazil; Mexico; Argentina; UAE; South Africa |
Key companies profiled |
Johnson & Johnson; Novartis AG; ITC Limited; Cipla Health Limited; Perrigo Company Plc.; Teva Canada; Philip Morris; British American Tobacco PLC |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global nicotine gum market report based on type, distribution channel, and region:
Nicotine Gum Type Outlook (Revenue, USD Million, 2017 - 2030)
2mg
4mg
Nicotine Gum Distribution Channel Outlook (Revenue, USD Million, 2017 - 2030)
Supermarkets/Hypermarkets
Convenience Stores
Pharmacies
Online
Nicotine Gum Regional Outlook (Revenue, USD Million, 2017 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Asia Pacific
China
India
Japan
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
UAE
South Africa
b. The global nicotine gum market size was estimated at USD 1,304.9 million in 2022 and is expected to reach USD 1,365.7 million in 2023
b. The global nicotine gum market is expected to grow at a compound annual growth rate of 5.6% from 2023 to 2030 to reach USD 2.0 billion by 2030
b. North America dominated the nicotine gum market with a market share of 29.9% in 2022. This is attributed to the increasing percentage of health-conscious consumers in the region as a result of campaigns and government initiatives in the region.
b. Some key players operating in the nicotine gum market include Johnson & Johnson, Novartis AG, ITC Limited, Cipla Health Limited, Perrigo Company Plc., Teva Canada, Philip Morris, British American Tobacco PLC
b. Key factors driving the market growth include increasing availability & acceptance of nicotine replacement therapy and increasing awareness of the health risks associated with smoking
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."